LNMG — Linike Medical Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $17.16m
- $17.16m
Annual income statement for Linike Medical, fiscal year end - October 31st, USD millions except per share, conversion factor applied.
2010 October 31st | 2011 October 31st | R2012 October 31st | 2013 October 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 0.059 | 0.016 | 0 | 0 |
| Cost of Revenue | ||||
| Gross Profit | — | 0.016 | 0 | 0 |
| Selling / General / Administrative Expenses | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 0.019 | 0.058 | 0.057 | 0.425 |
| Operating Profit | 0.04 | -0.042 | -0.057 | -0.425 |
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | 0.04 | -0.042 | -0.057 | -0.428 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | 0.034 | -0.042 | -0.057 | -0.428 |
| Net Income Before Extraordinary Items | ||||
| Net Income | 0.034 | -0.042 | -0.057 | -0.428 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Dilution Adjustment | ||||
| Diluted Net Income | 0.034 | -0.042 | -0.057 | -0.428 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | 0.125 | -0.155 | -0.209 | -0.126 |
| Dividends per Share |